These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Chemotherapy for ovarian cancer: an evidence-based approach. Geisler JP; Manahan KJ; Wiemann MC Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206 [TBL] [Abstract][Full Text] [Related]
3. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Benedetti Panici P; De Vivo A; Bellati F; Manci N; Perniola G; Basile S; Muzii L; Angioli R Ann Surg Oncol; 2007 Mar; 14(3):1136-42. PubMed ID: 17195909 [TBL] [Abstract][Full Text] [Related]
4. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224 [TBL] [Abstract][Full Text] [Related]
5. Advances in treatment of epithelial ovarian cancer. Kikkawa F; Nawa A; Ino K; Shibata K; Kajiyama H; Nomura S Nagoya J Med Sci; 2006 Jan; 68(1-2):19-26. PubMed ID: 16579172 [TBL] [Abstract][Full Text] [Related]
6. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030 [TBL] [Abstract][Full Text] [Related]
7. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique). Morice P; Leblanc E; Rey A; Baron M; Querleu D; Blanchot J; Duvillard P; Lhommé C; Castaigne D; Classe JM; Bonnier P; Hum Reprod; 2005 May; 20(5):1379-85. PubMed ID: 15817592 [TBL] [Abstract][Full Text] [Related]
8. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864 [TBL] [Abstract][Full Text] [Related]
9. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer. Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221 [TBL] [Abstract][Full Text] [Related]
10. Surgery in advanced epithelial ovarian cancer. Piver MS J Clin Oncol; 2001 Apr; 19(8):2364. PubMed ID: 11304790 [No Abstract] [Full Text] [Related]
11. Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance? Larsen E; Blaakaer J Acta Obstet Gynecol Scand; 2009; 88(4):373-7. PubMed ID: 19253061 [TBL] [Abstract][Full Text] [Related]
12. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534 [TBL] [Abstract][Full Text] [Related]
14. [Time interval between ovarian cancer surgery and chemotherapy--secondary publication?]. Larsen EP; Blaakaer J Ugeskr Laeger; 2009 Nov; 171(45):3265-8. PubMed ID: 19916194 [TBL] [Abstract][Full Text] [Related]
15. Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. Gadducci A; Ferrero A; Cosio S; Zola P; Viacava P; Dompé D; Fanelli G; Ravarino N; Motta M; Cristofani R; Genazzani AR Anticancer Res; 2006; 26(5B):3925-32. PubMed ID: 17094423 [TBL] [Abstract][Full Text] [Related]
16. Surgical management of epithelial ovarian cancer: a review of the literature. Dupont NC; Berman ML Minerva Ginecol; 2004 Dec; 56(6):547-56. PubMed ID: 15729207 [TBL] [Abstract][Full Text] [Related]
17. Routine appendectomy in epithelial ovarian carcinoma: is it necessary? Ayhan A; Gultekin M; Taskiran C; Salman MC; Celik NY; Yuce K; Usubutun A; Kucukali T Obstet Gynecol; 2005 Apr; 105(4):719-24. PubMed ID: 15802396 [TBL] [Abstract][Full Text] [Related]
18. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer. Capizzi E; Gabusi E; Grigioni AD; De Iaco P; Rosati M; Zamagni C; Fiorentino M Diagn Mol Pathol; 2008 Mar; 17(1):34-8. PubMed ID: 18303408 [TBL] [Abstract][Full Text] [Related]
19. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy. Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820 [TBL] [Abstract][Full Text] [Related]
20. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Maggioni A; Cosio S; Frassi E; LaPresa MT; Fuso L; Cristofani R J Clin Oncol; 2005 Feb; 23(4):751-8. PubMed ID: 15613698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]